Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Relapsed or Refractory Multiple Myeloma
Status:
Terminated
Trial end date:
2015-10-27
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well paclitaxel albumin-stabilized nanoparticle formulation
works in treating patients with multiple myeloma that has returned or did not respond to
treatment. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle
formulation, work in different ways to stop the growth of cancer cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading.